ArticleBlood advances2019
Sporadic and endemic Burkitt lymphoma have frequent
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.Nature immunology · 2026Article
- Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- Epstein-Barr virus infection shapes the genetic, transcriptomic, and immune microenvironment landscape of Burkitt lymphoma.Infectious agents and cancer · 2025Article
- FoxO1 signaling in B cell malignancies and its therapeutic targeting.FEBS letters · 2025Review
- Genomic landscape of virus-associated cancers.Nature communications · 2025Article
- Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues.Cancer discovery · 2024Article
- Mutant FOXO1 controls an oncogenic network via enhancer accessibility.Cell genomics · 2024Article
- Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia.Leukemia · 2023Article
- Article
- The discrete roles of individual FOXO transcription factor family members in B-cell malignancies.Frontiers in immunology · 2023Review
- The transcriptional program during germinal center reaction - a close view at GC B cells, Tfh cells and Tfr cells.Frontiers in immunology · 2023Review
- Article
- A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.The Journal of clinical investigation · 2022Article
- Oncogenic Mutations in the DNA-Binding Domain of FOXO1 that Disrupt Folding: Quantitative Insights from Experiments and Molecular Simulations.Biochemistry · 2022Article
- Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.Nature communications · 2022Article
- Article
- Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes.British journal of haematology · 2022Article
- FOXO1 forkhead domain mutants in B-cell lymphoma lack transcriptional activity.Scientific reports · 2022Article
- Reframing Burkitt lymphoma: virology not epidemiology defines clinical variants.Annals of lymphoma · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
Abstract
FOXO1 has an oncogenic role in adult germinal center-derived lymphomas, in which mutations, predominately within the AKT recognition motif, cause nuclear retention of FOXO1, resulting in increased cell proliferation. To determine the prevalence and distribution of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.